Law360, New York (August 19, 2009) -- Mylan Pharmaceuticals Inc. is appealing a federal judge's decision to validate Daiichi Sankyo Co. Ltd.'s patent for the active ingredient in its hypertension drugs Benicar and Azor and to enjoin Mylan from producing the generic version of these drugs until the patent expires in April 2016.
The company filed a notice of appeal Tuesday in the U.S. District Court for the District of New Jersey, objecting to Judge William J. Martini's Aug. 6 ruling that Mylan...
